In the therapeutic landscape of MM therapy, B-cell maturation antigen (BCMA)—one of the most specific and highly expressed antigen on myeloma cells—offers a promising target in RRMM. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.